Category Archives: Food & Drug Recalls

Nestlé Prepared Foods Company Announces Allergy Alert and Voluntary Recall of LEAN CUISINE® Dinnertime Selects™ Chicken Fettuccini Recall Due to Package Mislabeling

Nestlé Prepared Foods Company, a business unit of Nestlé USA, is initiating the voluntary recall of a limited quantity of LEAN CUISINE® Dinnertime Selects™ Chicken Fettuccini/UPC code 13800-14880. The affected product is marked with a production code of 1253595911G and has a “best before” date of October 2012. A small quantity—less than 200 packages–of LEAN CUISINE Dinnertime Selects Lemon Garlic Shrimp product was inadvertently placed into packaging for LEAN CUISINE Dinnertime Selects Chicken Fettuccini and possibly shipped to grocers in Alaska, Florida, Idaho, Oregon and Washington State.

Fruit Fresh Up, Inc. Recalls Fresh Cut Cantaloupe and Cut Mixed Fruit Containing Cantaloupe Distributed in New York State Because of Possible Health Risk

Fruit Fresh Up, Inc. of Depew, New York is recalling approximately 4,800 individual packages of FRESH CUT CANTALOUPE AND CUT MIXED FRUIT CONTAINING CANTALOUPE because they have the potential to be contaminated with listeria monocytogenes, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Although healthy individuals may suffer only short-term symptoms such as high fever, severe headache, stiffness, nausea, abdominal pain and diarrhea, listeria infection can cause miscarriages and stillbirths among pregnant women.

Prolab Proactively Recalls Some Protein Products in Order to Correct Labeling for Items That May Have Undeclared Milk and/or Wheat and Gluten Allergens

PROLAB NUTRITION INC. (PROLAB) is recalling some of its protein items that may contain undeclared milk, wheat and gluten allergens. People with an allergy or severe sensitivity to milk and/or wheat and gluten allergens may run the risk of a serious or life-threatening allergic reaction if they consume products containing these allergens.
Read The Complete Story!

FDA approves Cialis to treat benign prostatic hyperplasia

The U.S. Food and Drug Administration today approved Cialis (tadalafil) to treat the signs and symptoms of benign prostatic hyperplasia (BPH), a condition in which the prostate gland becomes enlarged, and for the treatment of BPH and erectile dysfunction (ED), when the conditions occur simultaneously. Cialis was approved in 2003 for the treatment of ED.

FDA Outlines Plans for an Outside Network of Scientific Experts

FDA’s Center for Devices and Radiological Health (CDRH) is soliciting comment on a plan to create a network of outside scientific experts who would provide staff with rapid access to specific specialized knowledge about emerging technology, as well as other topics. To further enrich this comment period, CDRH will also conduct a 12-week pilot of the network through Dec. 30, 2011.